Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

Vinod Ravi,Andrew S. Brohl,Sant P. Chawla,Steven Attia,Richard F. Riedel,David A. Liebner,Katherine Thornton,Atrayee Basu-Mallick,Darren W. Davis,Mario Cervantes,Wen Liu,Keyi Zhu,Delia Alvarez,Charles P. Theuer,Steven Robinson,Nicolas Penel,Silvia Stacchiotti,William D. Tap,Robin L. Jones,Robert G. Maki

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

2018

e23570Background: Endoglin (CD105) is an essential angiogenic receptor expressed on Angiosarcoma (AS) tumor cells and vessels that is upregulated following hypoxia and promotes resistance to VEGF i...

Keywords:

Endoglin
Pathology
Angiosarcoma
Pazopanib
Cancer research
Medicine
Hypoxia (medical)
Receptor
in patient
tumor cells
Downregulation and upregulation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations